Cited 0 time in
저분자량 헤파린으로 호전된 난치성 울혈반모양혈관병증
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 신재민 | - |
| dc.contributor.author | 문성훈 | - |
| dc.contributor.author | 성경제 | - |
| dc.contributor.author | 김정은 | - |
| dc.contributor.author | 고주연 | - |
| dc.contributor.author | 노영석 | - |
| dc.date.accessioned | 2022-07-16T06:44:28Z | - |
| dc.date.available | 2022-07-16T06:44:28Z | - |
| dc.date.issued | 2014-00 | - |
| dc.identifier.issn | 0494-4739 | - |
| dc.identifier.issn | 2713-7627 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/161002 | - |
| dc.format.extent | 2 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | 대한피부과학회 | - |
| dc.title | 저분자량 헤파린으로 호전된 난치성 울혈반모양혈관병증 | - |
| dc.title.alternative | Refractory Livedoid Vasculopathy Treated by Low-Molecular-Weight-Heparin | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.scopusid | 2-s2.0-84919624028 | - |
| dc.identifier.bibliographicCitation | 대한피부과학회지, v.52, no.11, pp 833 - 834 | - |
| dc.citation.title | 대한피부과학회지 | - |
| dc.citation.volume | 52 | - |
| dc.citation.number | 11 | - |
| dc.citation.startPage | 833 | - |
| dc.citation.endPage | 834 | - |
| dc.identifier.kciid | ART001932497 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.subject.keywordAuthor | Livedoid vasculopathy | - |
| dc.subject.keywordAuthor | Low-molecular-weightheparin | - |
| dc.subject.keywordAuthor | Refractory | - |
| dc.identifier.url | https://kiss.kstudy.com/thesis/thesis-view.asp?key=3277074 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
